Immunome (NASDAQ:IMNM) Stock Rating Reaffirmed by Leerink Partnrs

Leerink Partnrs restated their outperform rating on shares of Immunome (NASDAQ:IMNM – Free Report) in a research report released on Monday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Immunome’s Q4 2023 earnings at ($0.25) EPS, FY2023 earnings at ($0.50) EPS, Q1 2024 earnings at ($1.05) EPS, Q2 2024 earnings at ($0.12) EPS, Q3 […]

Related Keywords

Leerink Partnrs ,Hightower Advisors ,Blackrock Inc ,Immunome Company Profile ,Vanguard Group Inc ,Dorsey Wright Associates ,Renaissance Technologies ,Immunome Inc ,Free Report ,Stock Down ,Get Free Report ,Tower Advisors ,Immunome Daily ,Simmunome ,Nasdaq Imnm ,Imnm ,Medical ,Reiterated Rating ,